We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




ECOFF and AST Determined for Invasive Non-Typhoidal Salmonella

By LabMedica International staff writers
Posted on 04 Jul 2022

Invasive non-typhoidal Salmonella (iNTS) are a primary cause of bloodstream infections in low-resource settings (LRS). More...

The global burden has been estimated at 535,000 iNTS cases and 77,500 deaths per year. In sub-Saharan Africa, most iNTS are multidrug-resistant and non-susceptibility to third generation cephalosporins and fluoroquinolones has emerged.

In this context, azithromycin is an important candidate for oral iNTS treatment. Azithromycin is effective to treat typhoid fever and has, despite missing clinical efficacy data, been recommended for (switch to) oral iNTS treatment. Nevertheless, there are no international guidelines on azithromycin antibiotic susceptibility testing (AST) and interpretation for iNTS.

Clinical Scientists at the Institute of Tropical Medicine (Antwerp, Belgium) used EUCAST ECOFFinder to determine the minimum inhibitory concentrations (MIC; obtained by broth microdilution) epidemiological cut-off (ECOFF) and corresponding disk zone diameters of 515 iNTS from blood cultures in DR Congo, Burkina Faso, Rwanda, and Cambodia. Transferable resistance mechanisms were determined by polymerase chain reaction.

MIC values were determined with the semi-automated Sensititre AST System (Sensititre Nephelometer, AIM automated inoculator & Vizion digital MIC viewing system; Thermo Fisher Scientific, Waltham, MA, USA), with customized, single lot dry Sensititre plates (serial twofold azithromycin dilutions: 0.125 – 512 mg/L. For disk diffusion, they used 15 μg azithromycin disks from different brands (Oxoid/Thermo Fisher; BD, Becton, Dickinson and Company, Franklin Lakes, NJ, USA; Rosco, Taastrup, Denmark; Liofilchem, Abruzzi, Italy) and commercially prepared Mueller-Hinton agar plates (BD) for 161 wild and 198 non-wild type iNTS.

The investigators reported that azithromycin MIC ECOFF was 16 mg/L corresponding to a 12mm zone diameter; mphA was detected in 192/197 non-wild and 0/47 wild type iNTS. Categorical agreement was excellent (≥98%) for all methods. Essential agreement was very good for agar dilution (>90%), but moderate for gradient tests (MIC80%: 52 – 71% and MIC100%: 72 – 91%). Repeatability was good for all methods/brands. Inter-reader agreement was high for broth microdilution and agar dilution (all ≤1 twofold dilution difference) and disk diffusion (>96% ≤3mm difference), but lower for gradient tests (MIC80% & MIC100%: 83 − 94% ≤1 twofold dilution difference).

The authors concluded that Azithromycin ECOFF of iNTS was 16 mg/L, i.e. equal to Salmonella Typhi. Disk diffusion is an accurate, precise, and user-friendly alternatives for agar dilution and broth microdilution. Reading gradient tests at 100% instead of 80% inhibition improved accuracy and precision. The study was published on June 20, 2022 in the journal Clinical Microbiology and Infection.

Related Links:
Institute of Tropical Medicine 
Thermo Fisher Scientific 
Becton, Dickinson and Company
Rosco
Liofilchem


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
HPV Test
Allplex HPV28 Detection
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.